The third domestic application for approval of the new coronavirus vaccine was submitted for the vaccine of the American pharmaceutical company Moderna.
By September, the Japanese government has signed a contract to supply 50 million doses of the new coronavirus vaccine developed by Moderna, which is equivalent to 25 million people.
On the 5th, Takeda Pharmaceutical Company Limited, which handles distribution, submitted an application to the Ministry of Health, Labor and Welfare for approval for use in Japan.
The Moderna vaccine has already been inoculated in the United States and Canada, and the data of the clinical trial in the United States was submitted to the Ministry of Health, Labor and Welfare on the 5th.
In Japan, clinical trials have been conducted on 200 Japanese men and women over the age of 20 since January, and the data is expected to be submitted to the Ministry of Health, Labor and Welfare by May.
Regarding the vaccine for the new corona virus, of the three Western companies that have signed a contract to receive the supply from the Japanese government, the vaccine of the American pharmaceutical giant Pfizer was approved in February, and the vaccine of the British pharmaceutical giant AstraZeneca was also approved in February. The application has been submitted and is being reviewed.
Moderna "Important steps to be developed in Japan"
"This application for approval is an important step in the development of our vaccine in Japan," said Moderna, an American pharmaceutical company. Helping to achieve the goal of protecting the Japanese people from the new coronavirus. I would like to thank the Ministry of Health, Labor and Welfare and the people who participated in the clinical trial. "
Takeda Pharmaceutical Company "Provided as soon as possible"
Takeda Pharmaceutical Company commented, "We would like to express our sincere gratitude to those who participated in the clinical trials toward the realization of vaccine supply in Japan. We will strive to provide vaccines as soon as possible." I will.